Skip to main content
Jerald Radich, MD, Oncology, Seattle, WA

JeraldPRadichMD

Oncology Seattle, WA

Professor, Medicine, University of Washington School of Medicine

Dr. Radich is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Radich's full profile

Already have an account?

  • Office

    1959 NE Pacific St
    Seattle, WA 98195
    Phone+1 206-288-1000
    Fax+1 206-606-1025

Summary

  • Dr. Jerald Radich is an oncologist in Seattle, WA at the Fred Hutchinson Cancer Research Center. He received his medical degree from University of California Davis School of Medicine and has been in practice 34 years. He specializes in hematologic oncology and is experienced in molecular genetics and stem cell transplantation.

Education & Training

  • American College of Physicians
    American College of Physicians2008
  • Leukemia Society of America
    Leukemia Society of America1991 - 1994
  • University of Washington and the Fred Hutchinson Cancer Research Center
    University of Washington and the Fred Hutchinson Cancer Research Center1987 - 1990
  • Veterans Administration Medical Center Affiliated
    Veterans Administration Medical Center AffiliatedResidency, Chief Medical, 1986 - 1987
  • V.A. Hospital
    V.A. HospitalChief Residency, Chief Medical, 1986 - 1987
  • University of Washington
    University of WashingtonResidency, Internal Medicine, 1984 - 1986
  • University of Washington
    University of WashingtonInternship, Internal Medicine, 1983 - 1984
  • University of California, Davis, School of Medicine
    University of California, Davis, School of MedicineClass of 1983
  • Harvard University
    Harvard UniversityFellowship, 1977 - 1979
  • Harvard School of Public Health
    Harvard School of Public HealthM.S, Epidemiology, 1979
  • University of California
    University of CaliforniaPostgraduate studies, Biology, 1976 - 1977
  • University of California
    University of CaliforniaB.A, Biology, Honors, 1972 - 1976

Certifications & Licensure

  • WA State Medical License
    WA State Medical License 1984 - 2026
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014
  • NIH CA 18029: Project 4 2011
  • NIH CA 114762 2010
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Genomic Analyses Identify Recurrent MEF2D Fusions in Acute Lymphoblastic Leukaemia  
    Michael Borowitz, Hagop M Kantarjian, Cheryl L Willman, Stephen P Hunger, Selina M Luger, Clara D Bloomfield, Brent Wood, Jerald P Radich, Marina Konopleva, Stephen J ..., Nature
  • Hairy cell leukemia has a B-cell genotype.  
    Meyers FJ, Cardiff RD, Taylor C, Zuniga M, Radich JP, Hematol. Oncol. 2: 145-150
  • Rare occurrence of N-ras point mutations in chronic myeloid leukemia.  
    Collins SJ, Howard M, Andrews DF, Agura E, Radich J, Blood 73: 1028-1032
  • Join now to see all

Books/Book Chapters

Abstracts/Posters

  • Ultra-Accurate Assessment of Pretreatment ABL1 Kinase Domain (KD) Mutations in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic...
    Jerald P. Radich, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (A...
    Jerald P. Radich, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Characterization of Clonal Dynamics after Hematopoietic Cell Transplantation Using Ultra-Sensitive Duplex Sequencing
    Jerald P. Radich, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Patients, Borders, Money, and Mission: A Global Perspective of Chronic Myeloid Leukemia 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Analyses of Predictors of Durable Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Frontline or Second-Line Nilotinib 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) Is Active and Well-Tolerated in Adults with Newly-Diagnosed Acute Lympho... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • NIH Launches myeloMATCH Precision Medicine Trials for Myeloid Cancers
    NIH Launches myeloMATCH Precision Medicine Trials for Myeloid CancersOctober 23rd, 2024
  • myeloMATCH Program Opens Enrollment for Acute Myeloid Leukemia and MDS
    myeloMATCH Program Opens Enrollment for Acute Myeloid Leukemia and MDSOctober 22nd, 2024
  • S1712 Supports Adding Ruxolitinib to TKIs for CML
    S1712 Supports Adding Ruxolitinib to TKIs for CMLSeptember 20th, 2024
  • Join now to see all

Grant Support

  • Resistance And Relapse In Chronic Myeloid LeukemiaNational Cancer Institute2007–2011
  • Genomic Analysis Of Gene Copy Number In Thyroid CancerNational Cancer Institute2005–2007
  • Gene Expression Profile Of Progression &Response In CMLNational Cancer Institute2000–2003
  • Genetic Markers In Prognosis And Residual DiseaseNational Cancer Institute2002
  • Detection And Treatment Of Minimal Residual DiseaseNational Cancer Institute1997–2001
  • Gene Expression Profile Of Progression And Response In CNational Cancer Institute1999
  • Detection Of Minimal Residual Disease In Acute LeukemiaNational Cancer Institute1991–1993